4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000899243-18-000074
Chief Legal Officer sold 31,000 shares at an average $22.72 ($704,280)
- Chief Legal Officer acquired 16,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Dylan-Hyde Tyler · Chief Legal Officer
Table I: Non-derivative
8 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2017-12-28 | Exercise or conversion : show line 1 in the form | +700 | $14.43 | $10,101 | 115,904 | D |
| 2017-12-28 | Sale : show line 2 in the form | −700 | $21.75 | $15,225 | 115,204 | D |
| 2017-12-29 | Exercise or conversion : show line 3 in the form | +6,230 | $14.43 | $89,899 | 121,434 | D |
| 2017-12-29 | Sale : show line 4 in the form | −6,230 | $21.75 | $135,503 | 115,204 | D |
| 2017-12-29 | Exercise or conversion : show line 5 in the form | +9,070 | $12.57 | $114,010 | 124,274 | D |
| 2017-12-29 | Sale : show line 6 in the form | −1,070 | $21.75 | $23,273 | 123,204 | D |
| 2017-12-29 | Sale : show line 7 in the form | −8,000 | $23.76 | $190,080 | 115,204 | D |
| 2017-12-29 | Sale : show line 8 in the form | −15,000 | $22.68 | $340,200 | 100,204 | D |
| Open-market sales · 31,000 sh · avg $22.72 · $704,280 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2017-12-28 | Exercise or conversion : show line 9 in the form Stock Option (Right to Buy) | −700 | 64,300 | D |
| 2017-12-29 | Exercise or conversion : show line 10 in the form Stock Option (Right to Buy) | −6,230 | 58,070 | D |
| 2017-12-29 | Exercise or conversion : show line 11 in the form Stock Option (Right to Buy) | −9,070 | 44,263 | D |
Loading xslF345X03/doc4.xml…